Literature DB >> 25108642

Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's disease.

Hui Wu1, Fangyi Dong2, Ying Wang2, Qin Xiao2, Qiong Yang2, Jing Zhao3, Thomas J Quinn4, Sheng-di Chen5, Jun Liu6.   

Abstract

Catechol-O-methyltransferase (COMT) is one of the cardinal enzymes that metabolize dopamine and other catecholamine neurotransmitters in the central and peripheral nervous system. Recent studies have shown that the impact of COMT haplotypes on the development of wearing-off phenomenon is in dispute, while the relationship between COMT haplotypes and wearing-off phenomenon in ethnic Chinese population is lacking. The purpose of this study was to characterize the correlation between the Val158Met polymorphism in the COMT gene and the motor complication "wearing-off" in Chinese PD patients. We have sequenced the COMT gene in 259 PD patients and 257 healthy controls. Our results demonstrated that Met/Met homozygosity of the COMT Val158Met polymorphism was related to a decreased risk of developing wearing-off. This finding suggests that COMT Val158Met may affect susceptibility to wearing-off in PD.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COMT; Levodopa; Parkinson's disease; Wearing-off

Mesh:

Substances:

Year:  2014        PMID: 25108642     DOI: 10.1016/j.parkreldis.2014.07.011

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  Association of COMT Val158Met polymorphism with wearing-off susceptibility in Parkinson's disease.

Authors:  Jianxing Liu; Pan Chen; Meihua Guo; Lechun Lu; Lihua Li
Journal:  Neurol Sci       Date:  2014-11-04       Impact factor: 3.307

2.  Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.

Authors:  Huimin Chen; Jinping Fang; Fangfei Li; Liyan Gao; Tao Feng
Journal:  Neurol Sci       Date:  2015-01-24       Impact factor: 3.307

3.  Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Gita Vita Soraya; Zulvikar Syambani Ulhaq; Syifaus Shodry; Muhammad A'raaf Sirojan Kusuma; Sarah Herawangsa; Maharani Oryza Sativa; Aridin Gustaf; Dzakky Avecienna Nur Faridwazdi; Shinta Wulandari Florentia; Neila Raisa; Andi Kurnia Bintang; Muhammad Akbar
Journal:  Neurol Sci       Date:  2022-01-25       Impact factor: 3.307

4.  Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.

Authors:  Erinaldo Ubirajara Damasceno Dos Santos; Isaura Isabelle Fonseca Gomes da Silva; Amdore Guescel C Asano; Nadja Maria Jorge Asano; Maria De Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Mol Biol Rep       Date:  2020-11-05       Impact factor: 2.316

5.  From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.

Authors:  Sara Redenšek; Vita Dolžan; Tanja Kunej
Journal:  OMICS       Date:  2018-01

6.  Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson's disease.

Authors:  Qin Xiao; Yiwei Qian; Jiujiang Liu; Shaoqing Xu; Xiaodong Yang
Journal:  Transl Neurodegener       Date:  2017-04-26       Impact factor: 8.014

Review 7.  Clinimetrics of the 9- and 19-Item Wearing-Off Questionnaire: A Systematic Review.

Authors:  Carlos E Mantese; Artur Schumacher-Schuh; Carlos R M Rieder
Journal:  Parkinsons Dis       Date:  2018-04-01

8.  A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease.

Authors:  Debleena Guin; Manish Kumar Mishra; Puneet Talwar; Chitra Rawat; Suman S Kushwaha; Shrikant Kukreti; Ritushree Kukreti
Journal:  BMC Med Genomics       Date:  2017-09-19       Impact factor: 3.063

9.  Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.

Authors:  Małgorzata Michałowska; Małgorzata Chalimoniuk; Ewa Jówko; Iwona Przybylska; Józef Langfort; Beata Toczylowska; Anna Krygowska-Wajs; Urszula Fiszer
Journal:  Brain Behav       Date:  2020-02-05       Impact factor: 2.708

Review 10.  Pharmacogenetics of Parkinson's Disease in Clinical Practice.

Authors:  Jean-Christophe Corvol; Werner Poewe
Journal:  Mov Disord Clin Pract       Date:  2016-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.